Octanedioic Acid Hydroxyamide Phenylamide

Octanedioic Acid Hydroxyamide Phenylamide Uses, Dosage, Side Effects, Food Interaction and all others data.

Octanedioic Acid Hydroxyamide Phenylamide (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.

Octanedioic Acid Hydroxyamide Phenylamide
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Octanedioic Acid Hydroxyamide Phenylamide
Availability	Prescription only
Generic	Vorinostat
Vorinostat Other Names	Octanedioic acid hydroxyamide phenylamide, SAHA, Suberanilohydroxamic acid, Suberoylanilide hydroxamic acid, Vorinostat, Vorinostatum
Related Drugs	bexarotene, methoxsalen, Targretin, romidepsin, Targretin Gel
Type
Formula	C₁₄H₂₀N₂O₃
Weight	Average: 264.3202 Monoisotopic: 264.147392516
Protein binding	71%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Octanedioic Acid Hydroxyamide Phenylamide is a histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies.

For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

Octanedioic Acid Hydroxyamide Phenylamide is also used to associated treatment for these conditions: Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma, Recurrent Cutaneous T-cell lymphoma

How Octanedioic Acid Hydroxyamide Phenylamide works

Octanedioic Acid Hydroxyamide Phenylamide inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC₅₀< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.

Food Interaction

Take with food.

Octanedioic Acid Hydroxyamide Phenylamide Drug Interaction

Unknown: everolimus, contained in alcoholic beverages , sulfamethoxazole / trimethoprim, aspirin, prochlorperazine, dexamethasone, fentanyl, cyclobenzaprine, bismuth subsalicylate, levetiracetam, potassium chloride, levofloxacin, lidocaine topical, enoxaparin, psyllium, morphine, morphine, bismuth subsalicylate, acetaminophen / oxycodone, potassium phosphate / sodium phosphate

Octanedioic Acid Hydroxyamide Phenylamide Disease Interaction

Major: thromboembolismModerate: diabetes, GI disturbances, liver impairment, myelosuppression

Half Life

2 hours

Elimination Route

In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP). Octanedioic Acid Hydroxyamide Phenylamide is eliminated predominantly through metabolism with less than 1% of the dose recovered as unchanged drug in urine, indicating that renal excretion does not play a role in the elimination of vorinostat. However, renal excretion does not play a role in the elimination of vorinostat.